Race and HIV clinical trial participation

Donna Defreitas

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Purpose: This study was designed to examine at the role race/ethnicity plays in human immunodeficiency virus (HIV) clinical trial enrollment. Background: HIV clinical trials are vitally important for improving knowledge about medications and their impact on the pathogenesis of HIV/AIDS. African Americans are disproportionately underrepresented in HIV clinical trials. Methods: A 49-item survey was administered to 145 patients at an urban HIV clinic to explore race and HIV clinical trial participation. Results: Study participants were 56% Caucasian, 19% other, 16% African American, and 13% Hispanic. Fewer African Americans had been asked to participate in a trial compared to other groups (8% vs 24%) (p < .05). African Americans were less likely to volunteer for a trial compared to Hispanics and Caucasians, but African Americans did not differ significantly in their willingness participate in clinical trials vs other racial groups. In a regression model age, past trial participation, monetary gain, and comfort with the clinical setting predicted willingness to participate in a trial across racial groups (p < .05). Discussion: There is a strong need to identify strategies to increase African American enrollment in trials. Such strategies need to begin with trial recruiters actively seeking out African Americans for clinical trial enrollment.

Original languageEnglish (US)
Pages (from-to)493-499
Number of pages7
JournalJournal of the National Medical Association
Volume102
Issue number6
StatePublished - Jun 2010

    Fingerprint

Keywords

  • African americans
  • Clinical trial
  • HIV/AIDS

ASJC Scopus subject areas

  • Medicine(all)

Cite this